201 related articles for article (PubMed ID: 25733167)
1. IL10 receptor is a novel therapeutic target in DLBCLs.
Béguelin W; Sawh S; Chambwe N; Chan FC; Jiang Y; Choo JW; Scott DW; Chalmers A; Geng H; Tsikitas L; Tam W; Bhagat G; Gascoyne RD; Shaknovich R
Leukemia; 2015 Aug; 29(8):1684-94. PubMed ID: 25733167
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic Characterization of Very Early-Onset Inflammatory Bowel Disease with Interleukin-10 Signaling Deficiency: Based on a Large Cohort Study.
Zheng C; Huang Y; Hu W; Shi J; Ye Z; Qian X; Huang Z; Xue A; Wang Y; Lu J; Tang Z; Wu J; Wang L; Peng K; Zhou Y; Miao S; Sun H
Inflamm Bowel Dis; 2019 Mar; 25(4):756-766. PubMed ID: 30212871
[TBL] [Abstract][Full Text] [Related]
3. The clinical, molecular, and therapeutic features of patients with IL10/IL10R deficiency: a systematic review.
Sharifinejad N; Zaki-Dizaji M; Sepahvandi R; Fayyaz F; Dos Santos Vilela MM; ElGhazali G; Abolhassani H; Ochs HD; Azizi G
Clin Exp Immunol; 2022 Jun; 208(3):281-291. PubMed ID: 35481870
[TBL] [Abstract][Full Text] [Related]
4. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.
Mai Y; Yu JJ; Bartholdy B; Xu-Monette ZY; Knapp EE; Yuan F; Chen H; Ding BB; Yao Z; Das B; Zou Y; Young KH; Parekh S; Ye BH
Blood; 2016 Dec; 128(24):2797-2807. PubMed ID: 27737889
[TBL] [Abstract][Full Text] [Related]
5. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation.
Singh RR; Kim JE; Davuluri Y; Drakos E; Cho-Vega JH; Amin HM; Vega F
Leukemia; 2010 May; 24(5):1025-36. PubMed ID: 20200556
[TBL] [Abstract][Full Text] [Related]
6. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
Koivula S; Valo E; Raunio A; Hautaniemi S; Leppä S
Oncol Rep; 2011 Apr; 25(4):1183-90. PubMed ID: 21318224
[TBL] [Abstract][Full Text] [Related]
7. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
[TBL] [Abstract][Full Text] [Related]
8. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.
Liu D; Wang Y; Dong M; Guan S; Wang Y; Sun H; Wu N; Li S; Bai J; Chen F; Sun D; Jin Y
Ann Hematol; 2017 Feb; 96(2):227-235. PubMed ID: 27822610
[TBL] [Abstract][Full Text] [Related]
10. Alterations in T and B Cell Receptor Repertoires Patterns in Patients With IL10 Signaling Defects and History of Infantile-Onset IBD.
Werner L; Lee YN; Rechavi E; Lev A; Yerushalmi B; Ling G; Shah N; Uhlig HH; Weiss B; Somech R; Snapper SB; Shouval DS
Front Immunol; 2020; 11():109. PubMed ID: 32117262
[TBL] [Abstract][Full Text] [Related]
11. Enhanced TH17 Responses in Patients with IL10 Receptor Deficiency and Infantile-onset IBD.
Shouval DS; Konnikova L; Griffith AE; Wall SM; Biswas A; Werner L; Nunberg M; Kammermeier J; Goettel JA; Anand R; Chen H; Weiss B; Li J; Loizides A; Yerushalmi B; Yanagi T; Beier R; Conklin LS; Ebens CL; Santos FGMS; Sherlock M; Goldsmith JD; Kotlarz D; Glover SC; Shah N; Bousvaros A; Uhlig HH; Muise AM; Klein C; Snapper SB
Inflamm Bowel Dis; 2017 Nov; 23(11):1950-1961. PubMed ID: 29023267
[TBL] [Abstract][Full Text] [Related]
12. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
14. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.
Zhao T; Ren H; Wang X; Liu P; Yan F; Jiang W; Li Y; Li J; Gribben JG; Jia L; Hao J
Oncotarget; 2015 Sep; 6(29):27816-31. PubMed ID: 26315113
[TBL] [Abstract][Full Text] [Related]
16. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Bavi P; Abubaker J; Hussain A; Sultana M; Al-Dayel F; Uddin S; Al-Kuraya KS
Hum Pathol; 2008 Jun; 39(6):885-94. PubMed ID: 18400256
[TBL] [Abstract][Full Text] [Related]
17. IL10 inhibits starvation-induced autophagy in hypertrophic scar fibroblasts via cross talk between the IL10-IL10R-STAT3 and IL10-AKT-mTOR pathways.
Shi J; Wang H; Guan H; Shi S; Li Y; Wu X; Li N; Yang C; Bai X; Cai W; Yang F; Wang X; Su L; Zheng Z; Hu D
Cell Death Dis; 2016 Mar; 7(3):e2133. PubMed ID: 26962683
[TBL] [Abstract][Full Text] [Related]
18. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone.
Wu PY; Zhang XD; Zhu J; Guo XY; Wang JF
Hum Pathol; 2014 Aug; 45(8):1664-73. PubMed ID: 24931464
[TBL] [Abstract][Full Text] [Related]
19. The tumor suppressive role of inhibin βA in diffuse large B-cell lymphoma.
Jiang L; Si T; Yu M; Zeng X; Morse HC; Lu Y; Ouyang G; Zhou JX
Leuk Lymphoma; 2018 May; 59(5):1202-1212. PubMed ID: 28877610
[TBL] [Abstract][Full Text] [Related]
20. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
Slack GW; Steidl C; Sehn LH; Gascoyne RD
Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
